Skip to content
Study details
Enrolling now

Novel Drug Combinations for Gastric Cancer

AstraZeneca
NCT IDNCT05702229ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

240

Study length

about 4.7 years

Ages

18+

Locations

11 sites in CA, LA, MI +2

What this study is about

This trial is testing new drug combinations to treat gastric cancer. The treatment involves taking several different medications, and it will last about 1700 days. Participants will be adults.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take 5-Fluorouracil
  • 2.Take AZD0901
  • 3.Take AZD7789
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralInjection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), capecitabine, chemotherapy

Drug routes

oral (Oral Tablet), infusion

Endpoints

Primary: ORR (per RECIST 1.1 as assessed by Investigator)

Secondary: DoR per RECIST 1.1 based on Investigator assessment., OS, PFS per RECIST 1.1 as assessed by the Investigator